Compare ACCO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | VNDA |
|---|---|---|
| Founded | 1893 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 361.4M |
| IPO Year | 2005 | 2005 |
| Metric | ACCO | VNDA |
|---|---|---|
| Price | $4.22 | $5.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $14.90 |
| AVG Volume (30 Days) | 608.8K | ★ 810.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | ★ 141.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,524,700,000.00 | $216,105,000.00 |
| Revenue This Year | $3.10 | $21.35 |
| Revenue Next Year | $0.89 | $37.40 |
| P/E Ratio | $21.15 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $2.81 | $4.14 |
| 52 Week High | $4.39 | $9.91 |
| Indicator | ACCO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 32.17 |
| Support Level | $3.73 | N/A |
| Resistance Level | $4.36 | $5.46 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 73.00 | 9.72 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.